28th Conference of the European Network of Teratology Information Services
Budapest, September 2-5, 2017

SCIENTIFIC PROGRAMME
28th Conference of the European Network of Teratology Information Services (ENTIS),

September 2-5, 2017, Budapest, Hungary

Congress venue: Courtyard by Marriott Budapest City Center

Saturday, September 2

10.00 – 13.00   Board, Scientific Committee and Website Committee meetings

14.00   Begin of the conference: Welcome (Corinna Weber-Schoendorfer, Berlin, Germany)

14.00 – 17.00   ENTIS Business Meeting (open for all ENTIS members)

17.00 – 17.30   Poster visit (elevator pitch). Moderator: Gil Klinger, Tel Aviv, Israel

19.00   ENTIS dinner (registration required)

Sunday, September 3

9.00 – 12.15   Scientific part 1

9.00 – 9.10   Welcome (ENTIS president)

Chairs: President of ENTIS and Hedvig Nordeng, Oslo, Norway

9.10 – 9.40   Update on antiepileptic drugs and neurodevelopment – UK data (Laura Yates, Newcastle, UK)

9.40 – 10.10   What can ultrasound tell us about neurodevelopment and brain malformations? (Wolfgang Paulus, Ravensburg, Germany)

10.10 – 10.40   Coffee break

10.40 – 11.10   Special challenges related to risk communication about long-term neurodevelopmental outcomes (Heli Malm, Helsinki, Finland)

11.10 – 11.40   Latest on the Zika situation (Lavina Schuler-Faccini, Porto Alegre, Brazil)

11.40 – 12.10   Medication use in pregnancy - regulatory aspects and examples (Sarah Mee – MHRA, London, UK)

12.15 – 13.15   Lunch

13.15 – 13.45   Poster visit (elevator pitch). Moderator: Gil Klinger, Tel Aviv, Israel
13.45 – 15.00  Scientific part 2

Chairs: Asher Ornoy, Jerusalem, Israel & Herbert Juch, Graz, Austria

13.45 – 13.50  Introduction (Asher Ornoy, Jerusalem, Israel)

13.50 – 14.20  Measuring neurodevelopmental outcomes (Rebecca Bromley, Manchester, UK)

14.20 – 14.50  Neurodevelopmental outcomes in medication Safety Studies. Pros and cons. (Christina Chambers, San Diego, CA, USA)

14.50 – 15.00  Prospects (Chairs)

15.00 – 15.30  Coffee break

15.30 – 17.00  Scientific part 3

Chairs: Ursula Winterfeld, Lausanne, Switzerland & Corinna Weber-Schoendorfer, Berlin, Germany

15.30 – 16.00  State of the Art: cancer treatment in pregnancy (Kristel Van Calsteren, Leuven, Belgium)

16.00 – 17.00  ENTIS case reports on cancer therapy during pregnancy

16.00 – 16.10  Tretinoin therapy for acute promyelocytic leukemia during pregnancy (Heli Malm, Helsinki, Finland)

16.10 – 16.20  T-cell lymphoblastic lymphoma chemotherapy with febrile neutropenia and septic shock in pregnancy (Ksenia Zagorodnikov, Saint-Petersburg, Russia)

16.20 – 16.30  Acute myeloid leukemia during pregnancy (Gören M. Zafer, Istanbul, Turkey)

16.30 – 16.40  Radioactive iodine treatment for Papillary Thyroid Carcinoma during the First Trimester of Pregnancy (Nathalie Dinavitser, Zerifin, Israel)

16.40 – 17.00  Discussion

17.30 – 18.30  Meeting of the OTIS & ENTIS neurodevelopmental working group

**Monday, September 4**

**9.00 – 12.00  Scientific part 4: Free Communication**

Chairs: Orna Diav-Citrin, Jerusalem, Israel & Thierry Vial, Lyon, France
9.00 – 9.10 Pregnancy outcome following in-utero exposure to ondansetron: a prospective, comparative, observational cohort study (Orna Diav-Citrin, Jerusalem, Israel)

9.10 – 9.20 Use of Ondansetron during pregnancy and risk of major congenital malformations: Preliminary results of a Systematic Review and Meta-analysis (Hilal Erol Coşkun, Izmir, Turkey)

9.20 – 9.30 Pregnancy outcome after first trimester use of methyldopa: a prospective observational cohort study (Maria Hoeltzenbein, Berlin, Germany)

9.30 – 9.40 Pregnancy outcomes following fluoroquinolone exposure during pregnancy: Preliminary results of a systematic review and meta-analysis (Selin Acar, Izmir, Turkey)

9.40 – 10.10 What do you know about recent teratology studies? Quiz. Test yourself. (Corinna Weber-Schoendorfer, Berlin, Germany)

10.10 – 10.40 Coffee break

10.40 – 12.00 Scientific part 5: Free Communication

Chairs: Maurizio Clementi, Padua, Italy & Lucie Hubičková Heringová, Prague, Czech Republic

10.40 – 10.50 Long-term prenatal exposure to paracetamol is associated with DNA methylation differences in children with ADHD (Kristina Gervin, Oslo, Norway)

10.50 – 11.00 Paracetamol exposure in pregnancy and offspring ADHD: familial risk and confounding by indication (Eivind Ystrom, Oslo, Norway)

11.00 – 11.10 Pregnancy outcome after first trimester exposure to diclofenac: an observational cohort study from the German Embryotox Pharmacovigilance Institute (Stephanie Padberg, Berlin, Germany)

11.10 – 11.20 Metamizole use during first trimester – A prospective observational cohort study on pregnancy outcome (Katharina Dathe, Berlin, Germany)

11.20 – 11.30 Association of prenatal exposure to benzodiazepines and child internalizing problems: a sibling-controlled cohort study (Ragnhild E Brandlistuen, Oslo, Norway)

11.30 – 11.40 CRBN gene whole sequencing in Brazilians with Thalidomide embryopathy (Thayne W Kowalski, Porto Alegre, Brazil)

11.40 – 11.50 Patterns and predictors of hypothyroid medication use in relation to pregnancy: a drug utilization study (Anna Frank, Oslo, Norway)
11.50 – 12.00  Chronic Use of Psychotropic Medications in Breastfeeding Women (Nirit Kronenfeld, Jerusalem, Israel)

12.00 – 13.00  Lunch on your own

13.00 – 13.30  Poster visit (elevator pitch). Moderator: Gil Klinger, Tel Aviv, Israel.

13.30  Official end of ENTIS conference

Afternoon

14.00 – 17.30  Joint ETS/ENTIS education course on “Hormones and Brain Development”

(additional registration required)

Chairs: Asher Ornoy, Israel & Marta Axelstad, Denmark

14.00 – 14.15  Introduction (Asher Ornoy & Marta Axelstad)

14.15 – 14.45  Stress and stress hormones during fetal development: effects on disease susceptibility in later life (Sonja Entringer, Germany)

14.45 – 15.15  Thyroid hormones, thyroid diseases and their impact on fetal brain development. (Henning Tiemeier, the Netherlands).

15.15 – 15.30  Summary of main conclusions from Workshop on Thyroid Disruption, organized by the EU Commission, Paris, March 2017 (Marta Axelstad, Denmark)

15.30 – 16.00 Coffee break

16.00 – 16.30  Neurobehavioral and neurochemical changes in developing rodents exposed to EDC: criteria to predict a human hazard. (Gemma Calamandrei, Italy)

16.30 – 17.00  The validity of animal models for the understanding of human environmentally-induced neurobehavioral disorders: SSRIs as an example (Asher Ornoy, Jerusalem, Israel)

17.00 – 17.30  Round table: open discussion of all speakers and the audience: "How can we ensure optimal brain development?" Lessons from the different talks

19.00  ETS Welcome reception (additional registration required)

Tuesday, September 5
10.00 – 12.30  Symposium 1: Pre-term births (joint session of ETS and ENTIS)

Chairs: Steven Van Cruchten, Belgium & Corinna Weber-Schoendorfer, Germany

10.00 – 10.10  Introduction (Steven Van Cruchten, Belgium)

10.10 – 10.45  Preterm birth - epidemiology, consequences and possible interventions (Gil Klinger, Israel)

10.45 – 11.15  Coffee break

11.15 – 11.50  Recent insights in preterm brain injury gained from advanced neuroimaging: a review (Jeroen Dudink, the Netherlands)

11.50 – 12.25  Postnatal complications of preterm birth: the pig as a translational model (Thomas Thymann, Denmark)

12.30  Lunch  (included)